Massive Energy and Health Care Trades Highlight Insider Buying: Abbott Labs, Baker Hughes, Datawatch, Impac Mortgage and More
Last week, following the election, the insiders were back with a vengeance, and the buyers were out in full force.
Last week, following the election, the insiders were back with a vengeance, and the buyers were out in full force.
With the third-quarter earnings parade over, many of the windows prohibiting insider trades are opening back up, and the positive markets and extreme liquidity made the timing perfect for those selling.
While overall stocks have rallied, the tech sell-off has put many of the top dividend-paying stocks right back in the wheelhouse for investors looking for solid total return.
These five top industrial stocks to Buy all reside on the Focus names list at Jefferies, and they also may fare well in the new era of Trumponomics.
Optimism for tax cuts and growth in the economy is on the rise. That is just the ticket to help boost holiday sales, and some large cap potential winners may be just the right…
A new RBC research report makes the case that there are actually numerous reasons for a positive outlook on technology under a Trump presidency.
Analysts at Merrill Lynch have made a big move by adding a top consumer goods stock and a life sciences company to the firm's well-respected US 1 list of stocks, while removing a utility…
A new research report from JPMorgan makes the case that lowering the corporate tax rate could be huge for many large cap companies, including in the medical technology industry.
Now is a good time to add quality stocks in front of what is usually a very good time of the year for equities. These four stocks offer investors solid upside potential.
The UBS Dividend Ruler portfolio continues to outperform the overall market, and we continue to think that the outperformance will stay in place for the rest of the year and beyond.
Old-school growth stocks look like they really make sense now for investors looking ahead to 2017. These have been hit harder than some of their peers and may have bigger upside potential for investors…
One thing smart investors should keep in mind is things that are said and promised during a red-hot election need to be taken with a gigantic grain of salt.
After a dramatic conclusion to the presidential race, insider buying was dramatically larger than we have seen in months, and it could continue the rest of the year.
It was decidedly bullish to see so much insider buying come in after the election results. It was also bullish to see so little selling.
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
These companies are doing outstanding on their own, and the potential for additional revenue from a hot new Facebook project is just more fuel for the proverbial fire.
A new research report from Stifel makes the case that pure-play defense stocks may be a solid choice for investors to consider now.
The analysts at Merrill Lynch have made a big move by adding a top property and casualty company to the firm's well-respected US 1 list of stocks to Buy.
While there are no guarantees, these four stocks look solid and offer investors a chance to buy the companies below their acquisition price.
RBC thinks investors can buy these biotech stocks now, because the timing in their view is irrelevant, and they see the stocks de-risked and having mergers and acquisitions potential.